3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
55
Neoplasm Metastasis
7
Triple Negative Breast Neoplasms
6
Ovarian Neoplasms
6
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Advanced Breast Cancer
4
Prostatic Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Hereditary Sensory and Autonomic Neuropathies
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Solid Tumor
1
Solid Malignancies
1
Postmenopausal Women With ER+ HER2- Primary Breast Cancer
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lung Neoplasms
1
Liposarcoma
1
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
1
Interventions
tremelimumab
1
ixabepilone
1
durvalumab
1
ST 1481
1
Paclitaxel
1
Fulvestrant
1
Docetaxel
1
Axitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Solid Malignancies
×
Fulvestrant
×
Clear all
NCT02640755
2019-04-22
14C
AstraZeneca
Phase 1
Completed
4 enrolled
34 charts